TNFSF18 and acute myeloid leukemia: Other antibodies targeting TNF family members on AML cells, such as glucocorticoid-induced TNFR-related protein ligand (GITRL) and receptor activator for NF-κB ligand (RANKL), were manifested against primary AML cells in preclinical studies through the prevention of inhibitory signals into NK cells as well as the induction of ADCC [156–158].